MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio

Merit Medical Systems (MMSI) announced the acquisition of Biolife Delaware, L.L.C., a manufacturer of hemostatic devices, to bolster its Cardiac Intervention business. MMSI projects the acquisition will add $10-$11 million in revenues to the Cardiovascular segment from May 20 to Dec. 31, 2025, and has revised its full-year 2025 revenue guidance upward to $1.480-$1.501 billion, while adjusted EPS guidance decreased slightly to $3.28-$3.41 due to the acquisition being dilutive in the short term but accretive to adjusted margins in 2025 and EPS in 2026.

Analysis

Merit Medical Systems (MMSI) has acquired Biolife Delaware, aiming to enhance its hemostasis product portfolio within the Cardiac Intervention business, specifically targeting an estimated $350 million global market with Biolife's StatSeal and WoundSeal products. This strategic move is anticipated to contribute $10-$11 million in revenues from May 20 to December 31, 2025, prompting MMSI to revise its full-year 2025 revenue guidance upwards to $1.480-$1.501 billion, reflecting a 9.1-10.7% year-over-year increase. Despite this revenue uplift and an expected accretion to adjusted gross and operating margins in 2025, the acquisition will be dilutive to full-year 2025 GAAP net income and EPS, and has led to a slight downward revision in the 2025 adjusted EPS forecast to $3.28-$3.41 (a 1-5% YoY decrease). Management projects the acquisition will become slightly accretive to adjusted net income and EPS in 2026, and accretive to GAAP EPS thereafter. The market reacted mildly positively with a near 0.7% share price increase. MMSI has historically achieved synergies from acquisitions, exhibits a strong return on equity of 15.5% (above the industry's 14.3%), and reported a 14.7% earnings surprise in the last quarter, with its shares rallying 18.4% in the past year. The acquisition aligns with favorable industry prospects, as the global hemostasis market is projected to grow at a 9% CAGR between 2025 and 2030. However, it is noteworthy that MMSI currently holds a Zacks Rank #4 (Sell).

Key Decisions for Investors

• Investors should assess the long-term strategic value of the Biolife acquisition in the growing hemostasis market against the immediate GAAP EPS dilution and the marginally lowered 2025 adjusted EPS guidance.
• Carefully monitor MMSI's integration of Biolife and the company's ability to achieve the projected financial synergies, particularly the guided accretion to adjusted EPS in 2026 and GAAP EPS thereafter.
• Consider the contrast between the positive operational developments and revenue outlook from the acquisition, MMSI's strong historical performance, and its current Zacks Rank #4 (Sell) when evaluating positions.